Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2022 07:00 ET | Source: Imara, Inc.

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
December 14, 2021 07:00 ET | Source: Imara, Inc.

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
December 13, 2021 07:00 ET | Source: Imara, Inc.

Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
November 16, 2021 07:00 ET | Source: Imara, Inc.

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population ...
November 09, 2021 07:00 ET | Source: Imara, Inc.

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline...
November 04, 2021 16:01 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
November 04, 2021 09:17 ET | Source: Imara, Inc.

Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021

Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...
September 15, 2021 07:00 ET | Source: Imara, Inc.

Imara to Participate in Upcoming Investor Conferences

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
September 03, 2021 07:00 ET | Source: Imara, Inc.

Imara to Present at Upcoming Investor Conferences

BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
August 06, 2021 07:00 ET | Source: Imara, Inc.

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...